NKT cell adjuvants in therapeutic vaccines against hematological cancers

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Mattarollo, Stephen R ^a,b   Smyth, Mark J ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Galactosylceramide; hematological malignancies; Immune adjuvants; Immunotherapy; NKT cells; Tumor vaccine

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ANTINEOPLASTIC AGENT; BETA MANNOSYLCERAMIDE; CANCER VACCINE; CD1D ANTIGEN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; DRUG EFFICACY; HUMAN; INNATE IMMUNITY; MOLECULAR DYNAMICS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; VACCINE PRODUCTION;

EID: 84886944423     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22615     Document Type: Article

References (9)

1. Fais F, Morabito F, Stelitano C, Callea V, Zanardi S, Scudeletti M, et al. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer 2004; 109:402-11; PMID:14961579; http://dx.doi.org/10.1002/ijc.11723.
2. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 2008; 111:5637-45; PMID:18417738; http://dx.doi.org/10.1182/blood-2007-05-092866.
3. Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B, et al. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood 2012; 120:3019-29; PMID:22932803; http://dx.doi.org/10.1182/blood-2012-04-426643.
4. Chung Y, Qin H, Kang CY, Kim S, Kwak LW, Dong C. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood 2007; 110:2013-9; PMID:17581919; http:// dx.doi.org/10.1182/blood-2006-12-061309.
5. Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunol Cell Biol 2012; In press; PMID:23090488; http://dx.doi.org/10.1038/ icb.2012.58.
6. Moody DB, Briken V, Cheng TY, Roura-Mir C, Guy MR, Geho DH, et al. Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat Immunol 2002; 3:435-42; PMID:11938350.
7. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 2007; 204:2641-53; PMID:17923500; http://dx.doi.org/10.1084/jem.20070458.
8. nd, et al. Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity. J Clin Invest 2011; 121:683-94; PMID:21245578; http://dx.doi.org/10.1172/JCI42314.
9. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 103:383-9; PMID:14512316; http://dx.doi.org/10.1182/blood-2003-04-1155.